http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2520826-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3059b83559000195f351c509369cd697 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B3-00 |
| filingDate | 2013-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6f7426295c3e57e593e82ab8cf4539f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09553161af50c1927f4432380dddec6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7d15bda705cf5ad80ba9671e94c40f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163ba753ab2fac08cf50aa0acdd1f15d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8634b6230b5aa907482ab29120ce266f |
| publicationDate | 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2520826-C1 |
| titleOfInvention | Method for prediction of progression of diabetic retinopathy and diabetic macular oedema |
| abstract | FIELD: medicine.SUBSTANCE: blood plasma glycated haemoglobin and lachrymal vascular endothelial growth factor VEGF are measured by enzyme-linked immunosorbent assay. There are derived a criterion R1 characterising an intensity of the macular oedema; a criterion R2 characterising a degree of sensitivity threshold shift; a criterion R3 reflecting a character of relations of retinal morphological structures describing an intensity of the oedema as shown by the criterion R1, and a degree of diabetes mellitus compensation; criterion R4 reflecting the relation of the retinal morphological structures as shown by the criterion R1 and VEGF. The correlated relations of the criteria R1-R4 provide a basis to calculate Rcom that is an integral criterion of progression reflecting the developmental character and a risk of progression of diabetic retinopathy (DRP) and diabetic macular oedema (DMO). If Rcom?0.07, a neuroproliferative stage is diagnosed, and a low risk of progression of DRP and DMO is predicted. If 0.07<Rcom<0.18, a pre-proliferative stage is diagnosed, and a high risk of progression of DRP and DMO is predicted. The values within 0.18?Rcom?1.0 enables diagnosing a proliferative stage, and a high risk of progression of DRP and DMO with an unfavourable outcome for vision is predicted.EFFECT: method provides an objective quantitative assessment of a risk of development and progression of DRP with DMO, presenting an entire aspect of the disease, including morphological and functional changes of the central retina determining a visual acuity, an effect of VEGF on DRP and DMO pathogenesis, a degree of diabetes mellitus compensation.11 dwg, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2785861-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2603300-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2758576-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2610535-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2626681-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2643602-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2785270-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2800570-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2778970-C1 |
| priorityDate | 2013-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 136.